073-2126155
מובילה בדיאגנוסטיקה מולקולרית

שירותי מעבדה

Comments are closed.

  • Blueprint Genetics offers complete medical diagnostic solution in genetic testing with main focus on cardiologic disorders – from sequencing patient’s sample using NGS-panels (with up to 100% coverage and unrivalled 21 calendar days of turnaround time) to a final medical report. The laboratory in Helsinki, Finland is CLIA-certified, testifying the company's highest quality standards.
    Link to site
  • Centogene is a worldwide leader in the field of genetic diagnostic testing for rare hereditary diseases, with a broad test portfolio covering over 2300 genes, biochemical tests, biomarker and clinical whole exome sequencing and whole genome sequencing. Centogene’s mission is to support medical professionals with in-depth medical expertise to diagnose early and safe the reason for the patients burden.
    Link to site
  • Genome Diagnostics Nijmegen - a part of the Department of Human Genetics Nijmegen of the Radboud university medical center. Providing high quality and up to date diagnostics of hereditary disorders for patients and their families. The lab offers a large variety of medical genetic tests for >800 genes (>300 disorders)using Exome Sequencing Diagnostics and Targeted Sequencing Diagnostics (Ion Torrent Gene packages)
    Link to site
  • Myriad's next generation cancer panel - myRisk® Hereditary Cancer revolutionizes cancer testing, by blending both genetic test status and personal cancer family history; MyRisk identifies elevated risk for 8 important cancers by analyzing multiple, clinically significant genes. EndoPredict® is a multi-gene test for breast cancer patients, which provides physicians with information to devise personalized treatment plans for their breast cancer patients. EndoPredict is available in both a kit and a service format.
    Link to site
  • SEQUENOM - designs, develops, manufactures and markets innovative technology and tests. Sequenom developed MaterniT21 plus test, the first commercially available NIPT, which reports fetal sex, and both more common and rare fetal chromosomal abnormalities, from trisomies 21, 18, and 13 to fetal sex aneuploidies, trisomies 16 and 22, and select microdeletions. The MaterniT® GENOME test is the only genome-wide NIPT currently available, which provides information about gains or losses of chromosomal material across the genome.
    Link to site